| Literature DB >> 35160142 |
Hsin-Hao Liou1, Shu-Wei Tsai1, Miyuki Hsing-Chun Hsieh2, Yi-Jen Chen1, Jenn-Ren Hsiao1, Cheng-Chih Huang1, Chun-Yen Ou1, Chan-Chi Chang1, Wei-Ting Lee1, Sen-Tien Tsai1, David Shang-Yu Hung1.
Abstract
We evaluated objective and subjective swallowing function outcomes in patients with dysphagia treated for head and neck cancer (HNC) and identified risk factors for poor swallowing outcomes. Patients undergoing videofluoroscopic swallowing studies (VFSS) between January 2016 and March 2021 were divided into four groups according to primary tumor sites; post-treatment dysphagia was assessed. The penetration-aspiration scale (PAS) and bolus residue scale (BRS) were used to objectively assess swallowing function through VFSS. The Functional Oral Intake Scale (FOIS) was used for subjective analyses of swallowing statuses. To account for potential confounding, important covariates were adjusted for in logistic regression models. Oropharyngeal tumors were significantly more likely to have poor PAS and BRS scores than oral cavity tumors, and the patients with nasopharyngeal tumors were significantly less likely to have poor FOIS scores. Old age, having multiple HNCs, and a history of radiotherapy were associated with an increased odds of poor PAS scores (for all types of swallows), poor BRS scores (for semiliquid and solid swallows), and poor FOIS scores, respectively. This indicates using only subjective assessments may not allow for accurate evaluations of swallowing function in patients treated for HNC. Using both objective and subjective assessments may allow for comprehensive evaluations.Entities:
Keywords: dysphagia; head and neck cancer; objective assessment; outcomes; subjective assessment; swallowing
Year: 2022 PMID: 35160142 PMCID: PMC8836568 DOI: 10.3390/jcm11030692
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Flowchart depicting the inclusion of patients into the study population; * All 4 patients presented with dysphagia due to stroke before HNC diagnosis. Abbreviations: HNC, head and neck cancer; NCKUH, National Cheng Kung University Hospital; VFSSs, videofluoroscopic swallowing studies.
Characteristics of included patients.
| Different Tumor Types: | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Oral Cavity | NPC | Oropharynx | Hypopharynx | |||||||
|
| (%) |
| (%) |
| (%) |
| (%) |
| (%) | ||
| Male | 143 | (93) | 101 | (96) | 9 | (64) | 16 | (94) | 17 | (100) | <0.001 |
| Age (years), mean ± SD | 55.05 | ±9.49 | 54.93 | ±10.11 | 53.07 | ±6.89 | 57.71 | ±9.51 | 54.71 | ±7.14 | 0.581 |
| Time from HNC Dx *, median (IQR) | 12 | (26.4) | 10.8 | (24) | 23.4 | (43.2) | 12 | (31.2) | 16.8 | (14.4) | 0.131 |
| Time from surgery *, median (IQR) | 9.75 | 17.45 | 9.25 | 20.9 | 14.9 | 0 | 10.65 | 24 | 10.2 | 7.3 | 0.884 |
| Time from radiotherapy *, median (IQR) | 10.9 | 23.45 | 7.25 | 29.5 | 24.3 | 54.8 | 7.8 | 12.45 | 12.1 | 11.4 | 0.429 |
| T stage of cancer | 0.266 | ||||||||||
| 1 | 22 | (14) | 17 | (16) | 2 | (14) | 1 | (6) | 2 | (12) | |
| 2 | 36 | (24) | 27 | (26) | 1 | (7) | 5 | (29) | 3 | (18) | |
| 3 | 31 | (20) | 16 | (15) | 6 | (43) | 4 | (24) | 5 | (29) | |
| 4 | 57 | (37) | 41 | (39) | 2 | (14) | 7 | (41) | 7 | (41) | |
| Surgery Hx | 124 | (81) | 98 | (93) | 1 | (7) | 12 | (71) | 13 | (76) | <0.001 |
| Radiotherapy Hx | 101 | (66) | 59 | (56) | 14 | (100) | 13 | (76) | 15 | (88) | 0.001 |
| Both Surgery and radiotherapy Hx | 73 | (48) | 53 | (50) | 1 | (7) | 8 | (47) | 11 | (65) | <0.001 |
| Multiple HNCs | 46 | (30) | 40 | (38) | 0 | (0) | 2 | (12) | 4 | (24) | 0.006 |
| NG tude dependency | 24 | (16) | 16 | (15) | 1 | (7) | 2 | (12) | 5 | (29) | 0.069 |
* Indicated in months. Abbreviations: Dx = diagnosis; HNC = head and neck cancer; Hx = history; IQR = interquartile range; NG = nasogastric; SD = standard deviation.
Swallowing scores for different head and neck cancers.
| Different Tumor Types: | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Swallowing Scores: | Total | Oral Cavity | NPC | Oropharynx | Hypopharynx | ||||||
| Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | |||||||
| PAS_L | 1 | (3) | 1 | (1) | 2.5 | (5) | 3 | (3) | 2 | (3) | 0.010 |
| PAS_SL | 1 | (3) | 1 | (1) | 2.5 | (5) | 3 | (2) | 1 | (3) | 0.020 |
| PAS_S | 1 | (3) | 1 | (3) | 2.5 | (4) | 4 | (5) | 1 | (3) | 0.033 |
| BRS_L | 3 | (3) | 3 | (3) | 4 | (2) | 4 | (1) | 2 | (3) | 0.043 |
| BRS_SL | 3 | (3) | 3 | (3) | 3.5 | (2) | 4 | (1) | 2 | (3) | 0.211 |
| BRS_S | 3 | (3) | 3 | (3) | 2.5 | (3) | 4 | (1) | 2 | (3) | 0.505 |
| FOIS * | 4.5 | (2) | 5 | (1) | 6 | (2) | 4 | (1) | 3 | (3) | 0.014 |
* For FOIS score, a total of 126 analytical sample were included. This contained 91, 14, 11, 10 subjects from oral cavity, NPC, oropharynx and hypopharynx group, respectively. Abbreviations: BRS = Bolus Residue Scale; FOIS = Functional Oral Intake Scale; IQR = interquartile range; L = liquid; NPC = nasopharyngeal carcinoma; PAS = Penetration Aspiration Scale; SL = semiliquid; S = solid.
Ordinal logistic regression of VFSS outcomes.
| PAS_L | PAS_SL | PAS_S | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Tumor types | OR | (95% CI) |
| OR | (95% CI) |
| OR | (95% CI) |
|
| Oral cavity | ref. | ref. | ref. | ||||||
| NPC | 1.17 | (0.25, 5.56) | 0.847 | 1.91 | (0.39, 9.43) | 0.425 | 1.05 | (0.21, 5.21) | 0.956 |
| Oropharynx | 2.82 | (1.03, 7.72) | 0.043 | 3.64 | (1.32, 10.03) | 0.012 | 3.17 | (1.15, 8.73) | 0.025 |
| Hypopharynx | 3.00 | (1.11, 8.10) | 0.030 | 2.08 | (0.75, 5.78) | 0.161 | 1.90 | (0.68, 5.32) | 0.221 |
| Male | 1.46 | (0.31, 6.93) | 0.635 | 1.59 | (0.32, 7.93) | 0.575 | 0.56 | (0.13, 2.35) | 0.427 |
| Age | 1.04 | (1.01, 1.08) | 0.022 | 1.05 | (1.01, 1.09) | 0.012 | 1.04 | (1.00, 1.08) | 0.050 |
| Duration of disease | 1.02 | (0.87, 1.18) | 0.838 | 1.03 | (0.88, 1.20) | 0.709 | 1.04 | (0.89, 1.21) | 0.661 |
| T stage: | |||||||||
| 1 | ref. | ref. | ref. | ||||||
| 2 | 0.65 | (0.22, 1.91) | 0.435 | 0.62 | (0.20, 1.95) | 0.389 | 0.49 | (0.16, 1.49) | 0.207 |
| 3 | 0.79 | (0.26, 2.39) | 0.670 | 0.62 | (0.21, 1.85) | 0.414 | 0.63 | (0.20, 1.96) | 0.421 |
| 4 | 0.69 | (0.25, 1.92) | 0.478 | 0.94 | (0.34, 2.60) | 0.898 | 0.88 | (0.32, 2.45) | 0.812 |
| Surgery Hx | 0.85 | (0.30, 2.46) | 0.768 | 1.02 | (0.34, 3.03) | 0.974 | 0.83 | (0.28, 2.46) | 0.740 |
| Radiotherapy Hx | 1.49 | (0.68, 3.28) | 0.325 | 1.31 | (0.59, 2.90) | 0.501 | 1.23 | (0.55, 2.75) | 0.607 |
| Multiple HNCs | 0.80 | (0.37, 1.73) | 0.568 | 1.23 | (0.57, 2.66) | 0.605 | 0.99 | (0.45, 2.16) | 0.977 |
| BRS_L | BRS_SL | BRS_S | |||||||
| Tumor types | OR | (95% CI) |
| OR | (95% CI) |
| OR | (95% CI) |
|
| Oral cavity | ref. | ref. | ref. | ||||||
| NPC | 1.49 | (0.33, 6.71) | 0.604 | 1.38 | (0.31, 6.11) | 0.672 | 0.73 | (0.16, 3.30) | 0.681 |
| Oropharynx | 3.12 | (1.11, 8.76) | 0.031 | 2.86 | (1.04, 7.86) | 0.042 | 3.01 | (1.08, 8.39) | 0.035 |
| Hypopharynx | 0.64 | (0.24, 1.71) | 0.373 | 0.72 | (0.27, 1.91) | 0.504 | 1.15 | (0.43, 3.05) | 0.784 |
| Male | 1.74 | (0.42, 7.13) | 0.444 | 0.94 | (0.24, 3.73) | 0.935 | 0.72 | (0.18, 2.89) | 0.639 |
| Age | 1.02 | (0.99, 1.05) | 0.272 | 1.00 | (0.97, 1.04) | 0.792 | 1.01 | (0.98, 1.04) | 0.623 |
| Duration of disease | 1.07 | (0.92, 1.24) | 0.367 | 0.97 | (0.84, 1.13) | 0.725 | 1.00 | (0.86, 1.16) | 0.974 |
| T stage: | |||||||||
| 1 | ref. | ref. | ref. | ||||||
| 2 | 0.55 | (0.20, 1.48) | 0.235 | 0.42 | (0.15, 1.13) | 0.085 | 0.39 | (0.14, 1.07) | 0.066 |
| 3 | 0.91 | (0.32, 2.60) | 0.857 | 0.69 | (0.24, 1.95) | 0.481 | 0.85 | (0.30, 2.43) | 0.757 |
| 4 | 0.82 | (0.32, 2.12) | 0.680 | 0.71 | (0.27, 1.84) | 0.478 | 0.71 | (0.27, 1.85) | 0.483 |
| Surgery Hx | 0.65 | (0.23, 1.86) | 0.424 | 0.98 | (0.35, 2.78) | 0.971 | 1.19 | (0.42, 3.39) | 0.743 |
| Radiotherapy Hx | 0.72 | (0.36, 1.47) | 0.373 | 0.66 | (0.32, 1.33) | 0.244 | 0.60 | (0.29, 1.23) | 0.162 |
| Multiple HNCs | 1.89 | (0.94, 3.80) | 0.076 | 2.12 | (1.05, 4.27) | 0.036 | 2.28 | (1.12, 4.63) | 0.023 |
Abbreviation: BRS = Bolus Residue Scale; Cl = confidence interval; Hx = history; L = liquid; NPC = nasopharyngeal carcinoma; p = p value; PAS = Penetration Aspiration Scale; ref = reference; SL = semiliquid; S = solid.
Ordinal logistic regression of FOIS outcomes.
| FOIS | |||
|---|---|---|---|
| Tumor types | OR | (95% CI) |
|
| Oral cavity | ref. | ||
| NPC | 0.05 | (0.00, 0.69) | 0.025 |
| Oropharynx | 1.25 | (0.15, 10.25) | 0.833 |
| Hypopharynx | 4.58 | (0.64, 32.60) | 0.129 |
| Male | 0.58 | (0.06, 5.88) | 0.647 |
| Age | 1.04 | (0.98, 1.09) | 0.172 |
| Duration of disease | 1.11 | (0.89, 1.38) | 0.371 |
| T stage: | |||
| 1 | ref. | ||
| 2 | 0.99 | (0.18, 5.58) | 0.991 |
| 3 | 0.71 | (0.09, 5.39) | 0.738 |
| 4 | 1.09 | (0.21, 5.60) | 0.918 |
| Surgery Hx | 0.41 | (0.06, 2.74) | 0.354 |
| Radiotherapy Hx | 5.06 | (1.36, 18.87) | 0.016 |
| Multiple HNCs | 1.72 | (0.53, 5.61) | 0.371 |
Abbreviation: Cl = confidence interval; FOIS = Functional Oral Intake Scale; Hx = history; p = p value; ref = reference.
Number of patients with abnormal swallowing function among different tumor types.
| Total | Oral Cavity | NPC | Oropharynx | Hypopharynx | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| (%) |
| (%) |
| (%) |
| (%) |
| (%) | ||
| PAS_L ≥ 3 | 48 | (31) | 24 | (23) | 7 | (50) | 9 | (53) | 8 | (47) | 0.010 |
| PAS_SL ≥ 3 | 47 | (31) | 24 | (23) | 7 | (50) | 9 | (53) | 7 | (41) | 0.016 |
| PAS_S ≥ 3 | 51 | (33) | 27 | (26) | 7 | (50) | 10 | (59) | 7 | (41) | 0.019 |
| BRS_L ≥ 4 | 63 | (41) | 41 | (39) | 8 | (57) | 9 | (53) | 5 | (29) | 0.306 |
| BRS_SL ≥ 4 | 65 | (42) | 44 | (42) | 7 | (50) | 9 | (53) | 5 | (29) | 0.515 |
| BRS_S ≥ 4 | 66 | (43) | 44 | (42) | 6 | (43) | 9 | (53) | 7 | (41) | 0.859 |
Abbreviation: BRS = Bolus Residue Scale; L = liquid; NPC = nasopharyngeal carcinoma; PAS = Penetration Aspiration Scale; SL = semiliquid; S = solid.
Odds ratios of abnormal VFSS findings from multivariate logistic regression.
| PAS_L | PAS_SL | PAS_S | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Tumor types | OR | (95% CI) |
| OR | (95% CI) |
| OR | (95% CI) |
|
| Oral cavity | ref. | ref. | ref. | ||||||
| NPC | 2.53 | (0.42, 15.1) | 0.308 | 2.17 | (0.37, 12.75) | 0.392 | 0.88 | (0.15, 5.15) | 0.890 |
| Oropharynx | 3.51 | (1.1, 11.22) | 0.034 | 3.41 | (1.08, 10.75) | 0.036 | 3.49 | (1.11, 10.97) | 0.032 |
| Hypopharynx | 3.06 | (0.98, 9.53) | 0.054 | 2.23 | (0.71, 6.98) | 0.167 | 1.85 | (0.59, 5.78) | 0.289 |
| Male | 1.38 | (0.24, 8.07) | 0.722 | 1.45 | (0.25, 8.47) | 0.682 | 0.72 | (0.15, 3.59) | 0.689 |
| Age | 1.06 | (1.01, 1.11) | 0.018 | 1.04 | (1.00, 1.09) | 0.060 | 1.03 | (0.99, 1.07) | 0.195 |
| Duration of disease | 0.98 | (0.82, 1.16) | 0.784 | 1.03 | (0.86, 1.22) | 0.783 | 1.05 | (0.88, 1.25) | 0.567 |
| T stage: | |||||||||
| 1 | ref. | ref. | ref. | ||||||
| 2 | 1.26 | (0.33, 4.82) | 0.734 | 1.07 | (0.28, 4.06) | 0.917 | 0.75 | (0.21, 2.72) | 0.660 |
| 3 | 1.06 | (0.27, 4.22) | 0.930 | 1.15 | (0.30, 4.45) | 0.844 | 1.03 | (0.28, 3.83) | 0.967 |
| 4 | 1.16 | (0.32, 4.16) | 0.823 | 1.41 | (0.40, 4.91) | 0.594 | 1.14 | (0.34, 3.79) | 0.830 |
| Surgery Hx | 1.03 | (0.30, 3.59) | 0.960 | 0.93 | (0.27, 3.19) | 0.905 | 0.52 | (0.15, 1.77) | 0.297 |
| Radiotherapy Hx | 1.70 | (0.65, 4.44) | 0.278 | 1.62 | (0.63, 4.14) | 0.319 | 1.34 | (0.53, 3.36) | 0.537 |
| Multiple HNCs | 0.81 | (0.32, 2.06) | 0.655 | 1.06 | (0.42, 2.62) | 0.909 | 0.96 | (0.39, 2.36) | 0.931 |
| BRS_L | BRS_SL | BRS_S | |||||||
| Tumor types | OR | (95% CI) |
| OR | (95% CI) |
| OR | (95% CI) |
|
| Oral cavity | ref. | ref. | ref. | ||||||
| NPC | 1.27 | (0.23, 7.09) | 0.789 | 1.08 | (0.19, 6.10) | 0.927 | 0.80 | (0.13, 4.92) | 0.806 |
| Oropharynx | 1.83 | (0.59, 5.61) | 0.294 | 1.93 | (0.63, 5.90) | 0.251 | 2.06 | (0.67, 6.39) | 0.210 |
| Hypopharynx | 0.66 | (0.20, 2.16) | 0.488 | 0.62 | (0.19, 2.00) | 0.420 | 1.12 | (0.36, 3.45) | 0.843 |
| Male | 2.60 | (0.43, 15.66) | 0.298 | 2.31 | (0.40, 13.30) | 0.348 | 2.03 | (0.34, 12.24) | 0.441 |
| Age | 1.03 | (0.99, 1.07) | 0.215 | 1.02 | (0.98, 1.06) | 0.313 | 1.03 | (0.99, 1.07) | 0.130 |
| Duration of disease | 1.08 | (0.92, 1.27) | 0.366 | 0.97 | (0.82, 1.14) | 0.687 | 0.96 | (0.81, 1.15) | 0.673 |
| T stage: | |||||||||
| 1 | ref. | ref. | ref. | ||||||
| 2 | 0.70 | (0.22, 2.21) | 0.539 | 0.54 | (0.17, 1.69) | 0.290 | 0.50 | (0.16, 1.61) | 0.248 |
| 3 | 1.44 | (0.43, 4.84) | 0.553 | 1.05 | (0.32, 3.43) | 0.940 | 1.27 | (0.38, 4.22) | 0.702 |
| 4 | 1.25 | (0.42, 3.74) | 0.694 | 1.04 | (0.35, 3.05) | 0.950 | 1.02 | (0.34, 3.08) | 0.967 |
| Surgery Hx | 0.53 | (0.16, 1.75) | 0.296 | 0.72 | (0.22, 2.38) | 0.584 | 0.78 | (0.23, 2.63) | 0.691 |
| Radiotherapy Hx | 0.69 | (0.30, 1.58) | 0.384 | 0.73 | (0.33, 1.65) | 0.453 | 0.65 | (0.29, 1.48) | 0.309 |
| Multiple HNCs | 1.95 | (0.87, 4.37) | 0.105 | 1.96 | (0.89, 4.34) | 0.097 | 2.42 | (1.08, 5.42) | 0.031 |
Abbreviation: BRS = Bolus Residue Scale; Cl = confidence interval; Hx = history; L = liquid; NPC = nasopharyngeal carcinoma; p = p value; PAS = Penetration Aspiration Scale; ref = reference; SL = semiliquid; S = solid.